Summary
The NIH reports that 70% of medicines given to children have only been studied in adults; therefore, most drugs used to treat diseases in children are used off-label — without an adequate understanding of the appropriate dose, safety, or efficacy. Off-label prescribing has become the treatment of choice because of the lack of clinical trials in the pediatric population.
Register to download
Center for Pediatric Clinical Development Fact Sheet
You may also be interested in:
Page
Sustainability
We’re committed to meaningfully integrating sustainability considerations into our business practices and culture. The work we do has a global…
Blog
Ask the Experts: Why Do Rare Disease Clinical Trials Require a Unique Approach?
According to the National Organization for Rare Disorders (NORD), 90% of rare disorders do not have an FDA-approved treatment. We spoke with Juliane…
Case Study
Small Biotechnology Partnerships – A Success Story
PRA has experience partnering with small biotech firms, and we understand that they require a different approach than larger pharmaceutical…